Clinical Trial Update: To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing furmonertinib to placebo in EGFR mutation-positive stage II-IIIA non-small cell lung cancer after complete resection (with or without …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Furmonertinib (furmonertinib)

Snippet

Sponsor: Allist Pharmaceuticals, Inc. | Conditions: Non-small Cell Lung Carcinoma | Phase 3 | Status: RECRUITING